AstraZeneca to halt Cefotan sales
AstraZeneca will discontinue sales of the injectable antibiotic Cefotan after current inventory is depleted in March 2006. Bulk active ingredient supplier Astellas (formerly Yamanouchi) has stopped production of cefotetan, as has sterile end product manufacturer GlaxoSmithKline, AstraZeneca says. The company began notifying hospitals and wholesaler customers two years ago about the pending inventory depletion and potential therapeutic alternatives, including Merck's Mefoxin (cefoxitin). Cefotan global net sales in 2004 were $39.6 mil., with most of those in the U.S, AstraZeneca notes...
You may also be interested in...
Public Company Edition: Mergers with special purpose acquisition corporations may be heating up, but in addition to the Surrozen and Tango SPAC deals Recursion and Biomea launched initial public offerings. Also, Organon sells $5.6bn worth of notes to fund spinout from Merck & Co.
Efforts to improve trial diversity predate COVID-19, but the pandemic’s disproportionate effects on minority communities have brought the issue to the forefront.
Legend/J&J’s CAR-T cilta-cel and Chi-Med’s surufatinib would follow BeiGene’s Brukinsa, which won FDA approval in November 2019.